Hyperferritinemia: Pathophysiology, Etiologies, and Diagnostic Approach
European Journal of Haematology · 2026-12 · 117 (6) · 1442-1460
DOI: 10.1111/ejh.70285 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 06.08.2026. Verfasst von Youjin Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Legacy Health, Vancouver, Washington, USA. Hauptthemen laut MEDLINE: Hyperferritinemia, Ferritins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Objectives
Hyperferritinemia is common in adults, yet most lack true iron overload. Confusion among metabolic, inflammatory, genetic, and reactive causes drives under‐investigation and over‐treatment, compounded by SGLT2 inhibitors and, less certainly, GLP ‐1 receptor agonists. We synthesize the hepcidin‐ferroportin axis as the unifying mechanism and a transferrin saturation ( TSAT )‐guided pathway for workup.
Methods
Narrative review with structured PubMed , Embase, and Cochrane searches through April 2026, written to address the SANRA quality domains.
Results
Ferritin above 10 000 μg/L flags hemophagocytic lymphohistiocytosis ( HLH ), although the often‐cited 90%/96% performance is pediatric; adult HLH ‐2004 or HScore ≥ 169 reach 82%–95% sensitivity and 60%–94% specificity, lower in ICU populations. The Valenti consensus on metabolic hyperferritinemia is partially validated against clinical outcomes in cohorts applying its grading. A TSAT ‐guided pathway directs workup toward HFE genotyping, hepatic MRI , or metabolic evaluation; soluble transferrin receptor ( sTfR ) and the sTfR /log‐ferritin index complement ferritin in distinguishing iron deficiency from anemia of inflammation, though sTfR is itself influenced by inflammation.
Conclusions
The hepcidin‐ferroportin axis unifies adult hyperferritinemia under TSAT ‐guided evaluation, though the algorithm does not capture diabetes risk in C282Y homozygosity. SGLT2 inhibitors alter ferritin interpretation; GLP ‐1 receptor agonists may do so, though dedicated human evidence remains insufficient. Both warrant documentation at review.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine, Legacy Health, Vancouver, Washington, USA.
- Division of Hematology and Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
ORCID-Profile: Youjin Kim, Thomas C Landry, Lukas Seifer, Corinne LaVasseur, Kylee Martens, Joseph Shatzel
Förderung
- NHLBI NIH HHS
Zitieren
APA
Kim, Y., Landry, T. C., Seifer, L., LaVasseur, C., Martens, K., & Shatzel, J. (2026). Hyperferritinemia: Pathophysiology, Etiologies, and Diagnostic Approach. European Journal of Haematology, 117(6), 1442-1460. https://doi.org/10.1111/ejh.70285
Vancouver
Kim Y, Landry TC, Seifer L, LaVasseur C, Martens K, Shatzel J. Hyperferritinemia: Pathophysiology, Etiologies, and Diagnostic Approach. European Journal of Haematology. 2026;117(6):1442-1460. doi:10.1111/ejh.70285
BibTeX
@article{Kim2026,
author = {Kim, Youjin and Landry, Thomas C and Seifer, Lukas and LaVasseur, Corinne and Martens, Kylee and Shatzel, Joseph},
title = {Hyperferritinemia: Pathophysiology, Etiologies, and Diagnostic Approach},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {6},
pages = {1442--1460},
doi = {10.1111/ejh.70285}
}
EUVIMED